Biography
Wenwei Huang joined NIH in 2006. As a lead chemist, he has worked in various therapeutic areas, including oncology, neurological disorders, inflammation and infectious diseases. Through a collaboration with New York University, Huang developed a series of RORg inhibitors that was licensed to Orca Pharmaceuticals. Before joining NIH, Huang worked at ArQule, where his research focused on high-throughput chemistry. Huang received his Ph.D. from the University of Toronto and conducted his postdoctoral research at Emory University.
Research Topics
Huang is interested in medicinal chemistry and high-throughput chemistry. His current research focuses on developing drugs that block malaria transmission.